Boosting humoral and cellular immunity to pneumococcus by vaccination before and just after autologous transplant for myeloma

Abstract

These highlights do not include all the information needed to use PREVNAR 13 safely and effectively. See full prescribing information for PREVNAR 13.

Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation

“…19 A pretransplantation vaccine dose may generate immune memory, resulting in earlier peak immune responses, as described previously for pneumococcal vaccination. 20 Cell-mediated immunity responses in the current study were comparable with those in immunocompetent adults aged 50 years or older, while humoral immune responses were lower. 21 Vaccination before transplantation might be considered to improve such humoral immune responses.…”

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with immunocompromising conditions: a review of available evidence

“…At 6 and 12 months, only six and two responders, respectively, had persistent immunity by OPA responder criteria. NR Locke et al 36 Immunogenicity (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19, and 23F only) and safety of up to three doses of PCV13 in patients with MM receiving autologous hematopoietic cell transplant Prospective cohort; immunogenicity evaluated 3 months post-transplant United States/Academic hospital NR 6 Adults All patients who received pre- and post-transplant vaccinations were responders by IgG levels (significantly greater fold changes in PCV13 serotype-specific IgG titers compared with non-PCV13 serotype IgG levels). PCV13 was well tolerated and safety events were consistent with those previously reported for PCV13.…”

“…In the first, patients with MM undergoing autologous HCT were given PCV13: two patients received three doses (pretransplant and at 7–10 and 21–24 d following transplant); three patients received two doses (pretransplant and at d 21 post-transplant); and one patient received a single dose (pretransplant). 36 , 37 All patients who received pre- and post-transplant PCV13 vaccinations showed significantly greater IgG antibody responses against vaccine-specific serotypes compared with nonvaccine serotypes. There was a significant increase in serotype-specific IgG levels when compared with prevaccination levels for 6 of the 11 serotypes tested (3, 4, 6B, 9V, 18C, 23).…”

“…There was a significant increase in serotype-specific IgG levels when compared with prevaccination levels for 6 of the 11 serotypes tested (3, 4, 6B, 9V, 18C, 23). 36 The other study assessed a single dose of PCV13 in 20 patients aged 57 to 75 y with smoldering (i.e., early) MM. Immunogenicity was assessed for PCV7 serotypes (4, 6B, 9V, 14, 18C, 19F, 23F) at 1 month, 6 months, and 12 months post-vaccination.…”

“…Eight studies evaluated responses to PCV13 in patients with hematologic malignancies, including leukemia, MM, and mixed hematological disorders. [33][34][35][36][37][38][39][40]…”